Medical Management of Viral Diseases: Antivirals, Vaccines, Immunotherapy, and Supportive Care
Viral diseases are managed through a combination of direct antiviral agents, preventive vaccines, emerging immunotherapies, and supportive care. Treatment choice depends on virus, disease stage, host factors, and resistance patterns.
1. Antiviral Drugs (Direct-Acting)
| Drug Class | Examples | Key Indications |
|---|---|---|
| Neuraminidase inhibitors | Oseltamivir, zanamivir, baloxavir | Influenza A/B (treatment/prophylaxis) |
| Nucleoside/nucleotide analogs | Acyclovir, valacyclovir, ganciclovir, tenofovir | HSV, VZV, CMV, HBV, HIV |
| HCV protease/NS5A/polymerase inhibitors | Glecaprevir/pibrentasvir, sofosbuvir/velpatasvir | Hepatitis C (pan-genotypic, >95% SVR) |
| HIV ART | Integrase inhibitors (bictegravir, dolutegravir) + NRTIs | HIV-1 suppression (U=U) |
| RNA polymerase inhibitors | Remdesivir, molnupiravir, nirmatrelvir/ritonavir | COVID-19 (early outpatient/hospitalized) |
| Entry/fusion inhibitors | Maraviroc, enfuvirtide | HIV (resistant strains) |
2. Vaccines (Preventive & Therapeutic)
- Live attenuated: MMR, varicella, rotavirus, yellow fever, LAIV (flu).
- Inactivated: IPV, hepatitis A, rabies, IIV (flu).
- Subunit/recombinant: HepB, HPV, SARS-CoV-2 protein (Novavax).
- mRNA: Pfizer-BioNTech, Moderna (COVID-19); RSV (Arexvy).
- Viral vector: J&J, AstraZeneca (COVID-19); Ebola (Ervebo).
- Therapeutic vaccines: HPV therapeutic (in trials), HBV therapeutic.
3. Immunotherapy
- Monoclonal antibodies: Palivizumab (RSV prophylaxis), bebtelovimab (COVID-19, historical), ansuvimab (Ebola).
- Convalescent plasma/hyperimmune globulin: Polyclonal antibodies (limited utility, timing-critical).
- Interferons: IFN-α (HBV, HCV historical); IFN-λ (COVID-19 trials).
- Checkpoint inhibitors: PD-1/PD-L1 for virus-associated cancers (HPV+ HNSCC, EBV+ lymphoma, Merkel cell).
4. Supportive & Symptomatic Care
- Antipyretics (acetaminophen), analgesics, hydration, oxygen.
- Antihistamines (symptom relief only).
- Respiratory support (HFNC, NIV, intubation) for severe lower respiratory infection.
Principles
- Early antiviral initiation maximizes benefit (viral replication peak).
- Resistance monitoring (HIV, HCV, CMV, influenza).
- Vaccination remains the most cost-effective population-level strategy.
Rapid diagnostics (multiplex PCR, antigen tests) enable targeted therapy and infection control.
Viral Infections - Related Articles
- Why No Antibiotics for Viral Infections? Understanding Treatment Approaches
- Viral Pneumonia: Symptoms, Risks & Diagnosis | University of Maryland Medical Center
- ECHO Virus: Symptoms, Causes & Potential Complications
- Plague: Clinical Forms, Public Health Impact, and Modern Control Challenges
- Varicella Vaccine: Protection, Benefits & CDC Recommendations
- Protozoan Transmission Routes: From Contaminated Water to Insect Vectors
- Cruise Ship Food Poisoning: Risks, Causes & Prevention
